The Prostate Cancer Test That May Lead More Men to Harm Than Help

Many men diagnosed with prostate cancer will never be harmed by it.

As honest as that is, many people, even oncologists, find it difficult to believe.

For decades, men have been taught that finding prostate cancer early is one of the most important steps they can take to protect their health. The logic appears obvious: detect cancer as soon as possible, treat it quickly, and improve the chances of survival.

For some cancers, that approach has often saved lives.

Prostate cancer, however, presents a more complicated picture. Research has shown that many men develop abnormal prostate cells as they age, yet a substantial number of those abnormalities never progress into life-threatening disease. Some grow very slowly. Others may never cause symptoms at all.

This creates an uncomfortable question: If some prostate cancers would never have caused harm, what happens when we find them anyway?

The answer lies at the heart of one of the most debated topics in modern medicine: overdiagnosis.

For years, the conversation around prostate cancer has focused on finding more disease. Increasingly, however, researchers and physicians are asking a different question. Are we always helping patients when we find abnormalities, or are some men being exposed to unnecessary anxiety, procedures, and treatments that may never have improved their outcomes in the first place?

The answer is not as simple as supporters or critics of screening often suggest.

The challenge begins with a reality that makes prostate cancer unlike many other cancers.

Most patients do not care whether abnormal cells exist inside their prostate. What they care about is whether those cells will threaten their health, shorten their lives, or reduce their quality of life. Unfortunately, those are not always the same question.

Finding cancer cells is relatively easy compared to predicting what those cells will do over the next ten or twenty years.

This distinction is often overlooked in public discussions about screening. The assumption is that every cancer diagnosis represents a dangerous disease that requires immediate attention. Yet decades of research have shown that prostate cancer exists on a wide spectrum. Some tumors are aggressive and require treatment. Others may remain stable for years without causing significant harm.

Dr. Petteruti has explored this issue in several discussions, including Do Men Really Die From Prostate Cancer? What the Data Actually Shows. A recurring theme in that conversation is the distinction between identifying abnormal cells and identifying a life-threatening disease. While those concepts are often treated as interchangeable, they are not necessarily the same thing.

That difference shapes nearly every debate surrounding prostate cancer screening.

To understand why this issue remains controversial, it is important to recognize the strongest argument in favor of screening.

Early detection has been one of the most successful strategies in modern medicine. Finding disease before symptoms develop can create opportunities for intervention that might not exist later. It is therefore understandable why many physicians continue to support screening programs.

The PSA test emerged from this philosophy.

PSA, or prostate-specific antigen, is a protein produced by the prostate gland. Elevated levels can sometimes indicate prostate cancer. Because the test requires only a simple blood draw, it became a widely adopted tool for identifying men who might benefit from further evaluation.

From one perspective, the appeal is obvious. If an abnormal PSA identifies cancer before it spreads, treatment may be more effective and outcomes may improve.

Many physicians continue to view screening through this lens. Their concern is that reducing screening could allow aggressive cancers to go undetected until treatment options become more limited.

This position deserves serious consideration. The goal of screening has always been to reduce suffering and save lives.

The question is whether PSA testing consistently achieves that goal.

The challenge with PSA testing is not that it lacks value. The challenge is that PSA is not a cancer test.

It is a prostate test.

PSA levels can rise for many reasons, and cancer is only one of them. Benign prostate enlargement, inflammation, infection, age-related changes, and other non-cancerous conditions can all influence the result.

As a result, an elevated PSA does not necessarily tell us what is wrong. It simply tells us that additional questions may need to be asked.

This uncertainty often creates problems.

Many men hear the words “high PSA” and immediately assume they have cancer. Anxiety begins long before a diagnosis has been established. Additional testing is scheduled. Specialist appointments follow. The possibility of cancer starts to dominate the conversation.

Dr. Petteruti has addressed this issue in episodes such as Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies. He emphasized the fact that a single number cannot fully explain what is happening inside the prostate.

When PSA levels raise concern, the next step often involves a prostate biopsy. For many patients, this is the point where uncertainty begins to transform into diagnosis.

A biopsy allows physicians to collect tissue samples and examine them under a microscope. On the surface, the procedure seems straightforward. If cancer is present, the biopsy can identify it.

The problem is that finding abnormal cells is only part of the story.

A biopsy cannot always determine whether those cells will become dangerous in the future. Yet once a patient receives a cancer diagnosis, the psychological impact can be profound. The conversation quickly shifts from monitoring risk to deciding how aggressively to treat the disease.

Biopsies also carry risks of their own. Although serious complications are uncommon, the procedure remains invasive and can lead to bleeding, infection, discomfort, and additional medical interventions.

This is why the biopsy debate extends beyond the procedure itself. The real question is whether every elevated PSA warrants an invasive investigation.

In an Intellectual Medicine podcast, Dr. Petteruti has explored this issue in Think Twice Before a Prostate Biopsy: The Evidence You Need to Hear.

Once abnormal cells are discovered, another challenge emerges: The patient now carries a cancer diagnosis.

For many people, that label changes everything.

The word “cancer” naturally creates urgency. It is difficult to hear that diagnosis without imagining the worst possible outcome. Yet the biology of prostate cancer often refuses to fit neatly into those fears.

After a biopsy, tissue samples are frequently assigned a Gleason score. The score helps describe how abnormal the cells appear under a microscope and provides information about potential aggressiveness.

The problem is that Gleason scores do not predict the future.

They can estimate risk. They can provide probabilities. They cannot determine with certainty how a specific cancer will behave.

Some men with concerning pathology may experience little progression over many years. Others may develop aggressive disease despite appearing relatively low-risk initially.

This uncertainty creates a difficult situation for patients and physicians alike.

Faced with the possibility of progression, many men choose treatment because the alternative feels risky. Yet treatment decisions made under uncertainty can sometimes lead to consequences that are difficult to reverse.

As Dr. Petteruti discussed in Why Gleason Scores Fail Men With Prostate Cancer. In the podcast, he talked about how the score is an important piece of information. The concern is that it is sometimes treated as more predictive than it actually is.

One of the strongest arguments in the overdiagnosis debate centers on what happens after diagnosis. For men with aggressive disease, these aggressive treatments may provide tremendous benefit.

The challenge arises when the underlying cancer may never have become dangerous in the first place.

Every treatment carries risks. Urinary complications, erectile dysfunction, hormonal side effects, bowel issues, and other quality-of-life concerns can persist long after treatment ends. For some men, these effects become permanent.

This does not mean treatment is wrong, but maybe it means treatment should be proportional to the level of risk.

Dr. Petteruti has discussed the long-term consequences of treatment decisions in one of Intellectual Medicine’s podcast titled Sexual Recovery After Prostate Cancer Treatment: Restoring Function, Confidence, and Quality of Life. These conversations highlight an important reality: treatment outcomes should not be measured solely by whether cancer is removed. Quality of life is just as important.

One reason this debate remains unresolved is that no test can answer the question patients care about most.

What will happen to me?

PSA cannot answer that question.

Biopsies cannot answer that question.

Gleason scores cannot answer that question.

Even advanced genetic testing cannot answer that question with complete accuracy.

Medicine can estimate probabilities, but it cannot predict individual futures.

Two men with similar test results may experience completely different outcomes. One may live for decades without progression. Another may develop aggressive disease despite appearing low-risk at the outset.

This uncertainty frustrates patients, physicians, and researchers alike.

Yet acknowledging uncertainty is not a weakness. It is simply an honest reflection of where the science currently stands.

The inability to predict outcomes has encouraged many researchers to broaden the conversation. Rather than focusing exclusively on screening tests, some experts have begun paying closer attention to the factors that influence overall health and disease progression.

Some of those factors include:

• Obesity

• Physical inactivity

• Poor diet

• Smoking

• Metabolic disease

• Chronic inflammation

These factors influence far more than cardiovascular health. They may also affect how the body responds to abnormal cells over time.

This broader perspective does not replace screening. Instead, it adds another layer to the discussion.

The debate surrounding prostate cancer screening is often framed as a battle between those who support testing and those who oppose it. The reality is far more nuanced.

PSA testing can identify abnormalities. Biopsies can identify cancer. Gleason scores can provide useful information. These tools have value.

What remains uncertain is how that information should be used in every individual case.

An elevated PSA is not a diagnosis. A biopsy finding is not a prediction of the future. A cancer label does not automatically mean treatment is necessary.

The strongest lesson from decades of research may be that finding disease and helping patients are not always the same thing. Sometimes they overlap perfectly. Sometimes they do not.

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.